Browse every story filed under this topic, curated from trusted publishers around the world.
Overweight and obesity, which have increased steadily since 1995, seem to be key factors in the rise of cancer cases, experts suggest.
Read full story →
Researchers have become increasingly concerned in recent years about trends showing rising cancer rates in young adults, such as bowel …
Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
Poor housing, obesity and the effects of deprivation have been suggested as underlying cause.
With the recent launch of Novo Nordisk’s Wegovy pill opening the oral GLP-1 market for obesity, the company has now …
Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, …
The Trump administration has dropped a plan for insurers to provide cheap weight loss drugs to seniors through a Medicare …
What You Should Know The Launch: Amazon One Medical has rolled out a nationwide GLP-1 management program that explicitly integrates …
Health insurers would likely face a financial strain by participating in the Medicare pilot.
Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
You've seen all articles for #obesity.
Check back
soon
for new stories.